Related Experiment Video

Updated: Sep 26, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Monoclonal antibody drug immunoconjugates for targeted treatment of cancer

Pamela A Trail1, H Dalton King, Gene M Dubowchik

  • 1pamela.trail.b@bayer.com

Cancer Immunology, Immunotherapy : CII
|April 18, 2003
PubMed

Insights

Monoclonal antibody immunoconjugates selectively deliver potent drugs to tumors, enhancing efficacy and reducing toxicity. This approach shows promise for cancer treatment, with some conjugates already in clinical trials and one approved for leukemia.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Monoclonal antibodies (mAbs) targeting tumor-associated antigens (TAAs) or tumor vasculature can be linked to potent drugs.
  • These mAb immunoconjugates aim to selectively deliver therapeutics to tumors, potentially improving antitumor efficacy and reducing systemic toxicity.

Purpose of the Study:

  • To review the properties of tumors, mAbs, linkers, and drugs that influence the efficacy, potency, and selectivity of immunoconjugates for cancer treatment.
  • To highlight the demonstrated feasibility and ongoing evaluation of immunoconjugates in clinical settings.

Main Methods:

  • Review of preclinical and clinical data on monoclonal antibody immunoconjugates.
  • Analysis of factors influencing immunoconjugate performance, including antibody internalization, linker stability, drug potency, and tumor-specific antigen expression.

Main Results:

  • Several immunoconjugates, especially those with internalizing antibodies and tumor-selective linkers, show significant activity in preclinical models.
  • Immunoconjugates delivering doxorubicin, maytansine, and calicheamicin are in clinical trials, with Gemtuzumab ozogamicin approved for AML.

Conclusions:

  • The use of immunoconjugates as cancer therapeutics is feasible and supported by clinical evidence.
  • Optimizing tumor characteristics, mAb properties, linker technology, and drug selection is crucial for developing effective immunoconjugate therapies.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...